Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI

Sean Turbeville, Helen Nicely, J. Douglas Rizzo, Tanya L. Pedersen, Paul J. Orchard, Mitchell E. Horwitz, Edwin M. Horwitz, Paul Veys, Carmem Bonfim, Amal Al-Seraihy

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome) is one of approximately 50 known lysosomal storage disorders. MPS VI is characterized by an absence or deficiency of N-acetylgalactosamine 4-sulfatase (arylsulfatase B) resulting in accumulation of dermatan sulfate. Prior to the availability of enzyme replacement therapy (ERT), the clinical management of MPS VI was limited to supportive care and allogeneic hematopoietic stem cell transplantation (HSCT); however, due to the rarity of this disease, little is known about the long-term outcomes of HSCT for MPS VI. The following retrospective study was performed using aggregate data gathered by the Center for International Blood and Marrow Transplant Research (CIBMTR) between 1982 and 2007 to determine survival probability for patients with MPS VI following allogeneic HSCT. This analysis identified 45 MPS VI patients with a median age of 5. years (range, 1-22. years) at the time they received an allogeneic HSCT. Cumulative incidence (95% CI) of acute graft-vs.-host disease at 100. days was 36% (21-53%). Probability of survival was 78% (65-89%) at 100. days and 66% (52-79%) at 1 and 3. years. While these data are based upon small numbers of recipients, they represent the largest series to date and may help clinicians assess the relative risks and benefits of currently available therapies.

Original languageEnglish (US)
Pages (from-to)111-115
Number of pages5
JournalMolecular Genetics and Metabolism
Issue number2
StatePublished - Feb 2011


  • Arylsulfatase B
  • Enzyme replacement therapy
  • Galsulfase
  • Hematopoietic stem cell transplantation
  • Mortality
  • Mucopolysaccharidosis VI

Fingerprint Dive into the research topics of 'Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI'. Together they form a unique fingerprint.

Cite this